Enrichment of C5a-C5aR axis predicts poor postoperative prognosis of patients with clear cell renal cell carcinoma

Wei Xi; Li Liu; Jiajun Wang; Yu Xia; Qi Bai; Ying Xiong; Yang Qu; Qilai Long; Jiejie Xu; Jianming Guo

doi:10.18632/oncotarget.13108

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Enrichment of C5a-C5aR axis predicts poor postoperative prognosis of patients with clear cell renal cell carcinoma

Wei Xi, Li Liu, Jiajun Wang, Yu Xia, Qi Bai, Ying Xiong, Yang Qu, Qilai Long, Jiejie Xu and Jianming Guo _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2016; 7:80925-80934. https://doi.org/10.18632/oncotarget.13108

Metrics: PDF 2048 views | HTML 2242 views | ?

Abstract

Wei Xi1,*, Li Liu1,*, Jiajun Wang1,*, Yu Xia1, Qi Bai1, Ying Xiong1, Yang Qu1, Qilai Long1, Jiejie Xu2, Jianming Guo1

1Department of Urology, Zhongshan Hospital, Fudan University, Shanghai 200032, China

2Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China

*These authors contributed equally to this work

Correspondence to:

Jiejie Xu, email: [email protected]

Jianming Guo, email: [email protected]

Keywords: ccRCC, C5aR, C5a-C5aR axis, prognosis, nomogram

Received: September 20, 2016 Accepted: October 28, 2016 Published: November 04, 2016

ABSTRACT

Anaphylatoxin C5a and its receptor C5aR on cancer cells constitute a vital axis to cancer progression. In this study, we measured C5aR level by immunohistochemistry in the same cohort of our previous C5a research, and C5a-C5aR axis status was determined by synthesizing C5a and C5aR data. C5aR was an adverse independent prognostic factor for ccRCC patients. Kaplan-Meier analyses revealed the unique position of both C5a and C5aR high population in postoperative survival, based on which patients were then shunted into C5a-C5aR enriched and non-enriched groups. Obviously, C5a-C5aR enriched patients significantly had a poorer overall survival (OS) and recurrence free survival (RFS) compared with non-enriched ones, and the independence of C5a-C5aR axis was verified by multivariable analyses (HR 2.118, P = 0.001 for OS, HR 1.715, P = 0.035 for RFS). Established nomograms based on our findings reflected much better predicting accuracy in contrast with most common used TNM and Fuhrman systems. Meanwhile, consistent with HR, C5a-C5aR axis in this study held its advantages over C5a and C5aR for OS prediction by c-index analyses, rather than RFS prediction.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 13108

Publication Alerts

Research Papers:

Enrichment of C5a-C5aR axis predicts poor postoperative prognosis of patients with clear cell renal cell carcinoma

Abstract